On February 6, 2020 Zetagen Therapeutics, Inc., a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, reported the close of $5.34M Series A funding round (Press release, Zetagen Therapeutics, FEB 6, 2020, View Source [SID1234643690]). The financing will accelerate the growth of the Company’s ongoing clinical programs for ZetaMet (Zeta-BC-003), a synthetic, small-molecule, inductive biologic being developed to target and resolve metastatic lesions while inhibiting future tumor growth.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are extremely pleased to have reached such an important milestone in Zetagen’s advancement as a biopharmaceutical company, " said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. "This funding is paramount to accelerating our clinical programs around ZetaMet (Zeta-BC-003) by adding the necessary scientific infrastructure that will allow us to prepare for future human clinical trials."

ZetaMet (Zeta-BC-003) is a novel molecular pathway paired with a proprietary, drug-eluting implant technology. The novel therapy is designed to resolve tumor growth, inhibit pain, and regenerate bone. Zetagen exclusively licensed the platform technology from the State University of New York in 2016.